Digital & Computational Pathology - Head of Translational Research, Top 20 Pharma

In this interview, a head of translational research at a top 20 pharma discusses their use and implementation of digital pathology. This stakeholder uses digital pathology to subtype and group patients for clinical trials and retrospective analysis. They estimate using digital pathology on a few thousand slides per year and expect usage to scale with the establishment of a framework for data management and analysis. The stakeholder was familiar with several digital pathology vendors, including Roche, Akoya, PathAI, Nucleai, Owkin, and Tempus. Pain points for this stakeholder include data management and data analysis. Key market trends this stakeholder discusses include the potential for digital pathology to be transformative in quantifying and scaling traditional pathology workflows, and the importance of demonstrating the utility and worth of digital pathology tools for commercial implementation.

‍